Home Page Lawsuits Filed Lawsuit: Bladder Cancer Victims File Actos Lawsuit
Bladder Cancer Victims File Actos Lawsuit
Seattle, WA: A nationwide lawsuit has been filed by people who have taken the diabetes medication Actos (pioglitazone) alleging it is associated witht the development of bladder cancer. The lawsuit is not a class action, rather each qualifying individual will seek damages consistent with the merits of his or her individual case. To qualify to join the Actos lawsuit, one must meet basic criteria, including that one has taken Actos and developed bladder cancer.
Actos is one of the most popular diabetes drugs in the world. Recently, however, studies have shown that Actos use is linked to serious side effects, particularly bladder cancer. These studies show that the longer one takes Actos, the greater the risk of developing bladder cancer. As a result of this mounting scientific evidence, the FDA has issued warnings regarding Actos and bladder cancer. In France, the French Agency for Safety of Health Products recalled Actos from the market on June 9, 2011. Regulators in Germany recommended that physicians not prescribe it.
If you or a loved one took Actos and developed bladder cancer, you may have a case against the manufacturer of Actos. Time limits exist that limit the amount of time you have to join the lawsuit, so if you think you may have a claim.
Actos Bladder Cancer Lawsuit Legal HelpIf you or a loved one has suffered damages in this case, please click the link below and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.
Last updated on
LEGAL ARTICLES AND INTERVIEWS
Actos Bladder Cancer Lawsuits Continue in the US and Canada
Huntsville, AL: As Takeda Pharmaceutical Company prepares to release its Q4 strategy, litigation over Actos bladder cancer continues unabated [READ MORE]
READ MORE [ Drugs/Medical Settlements and Legal News ]
READ MORE [ Personal Injury Settlements and Legal News ]
bladder cancer damage, renal and liver failure.
ADD YOUR COMMENT ON THIS ISSUE